For those of you who saw our press release earlier this week, you noticed that we have rebranded this system as the Purion M. The Purion M is the first tool in our next-generation Purion implant platform and further advances the best Axcelis technology. The Purion M provides significant advantages over our competition, particularly with improvements in yield, for applications like HALO implants, an increase productivity for implants that utilize the system's 335 keV extended energy range. We believe that the Purion M will allow us to become a significant player in the medium current segment, an area in which we have had a relatively small presence and market share. We are working on additional Purion M evaluations, which will be addressed in future announcements.
The Optima XEx continues to ship to the worldwide chipmakers as they add capacity to their fab. Its excellent reliability, broadest energy range and superior productivity, make it the leading system for high energy implantation. And in dry strip, we are building on the momentum our Integra platform had in 2011. Our 2 evaluations are proceeding well, further demonstrating the superior performance of the Integra ES for advanced strip application.
Customers are confident in Axcelis' ability to deliver strong technology promotions that provide superior process performance and the lowest cost of ownership. Our customers continue to strongly support and work with us to extend our reach as they develop solutions for advanced technology challenges.
I'm now going to turn the call over to Jay, who will discuss our financial results for Q2, our restructuring actions and our guidance for Q3.Read the rest of this transcript for free on seekingalpha.com